DefiniGEN

DefiniGEN and Atelerix collaborate to ship in vitro cell models internationally without the need for freezing or cryopreservation

3 June 2024 -- Cambridge and Newcastle, UK -- DefiniGEN and Atelerix today announced they have successfully shipped in vitro liver models from the UK to a top tier pharma customer in the US. The agreement between the companies combines DefiniGEN’s mechanistically relevant iPSC hepatocytes (Opti-Heps) with Atelerix's hydrogel preservation technology, which prevents loss of...

DefiniGEN Raises £1.5M ($2.29M USD) in Follow-on Funding

Cambridge, UK, 23rd May 2016: DefiniGEN, a leading provider of stem cell life science products, has announced that it has raised £1.5m ($2.29m) in follow-on funding. The round was led by Cambridge Enterprise, the commercialization arm of the University of Cambridge, and 24 Haymarket, with key investors Dr Jonathan Milner (Chairman), Providence Investment Company, Parkwalk,...
DefiniGEN Ltd, Babraham Research Campus, Maia Building, Babraham, Cambridge, CB22 3AT, United Kingdom

+44 (0)1223 497113